arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ALLURION TECHNOLOGIES, INC.

ALUR
Price unavailable
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
18 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
51
Health
Fair
Moderately Bearish
auto_awesome

Analytical Summary

ALLURION TECHNOLOGIES, INC. faces fundamental challenges with weakness in Profit Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap
Dividend Yield
Revenue Growth -47.2%
Op. Margin -126.6%
ROIC 4.8%
FCF / Share $-0.24
Trailing P/E
Price / Book
FCF Yield
Debt / Equity 0.00
info Valuation on last close.

18-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.95M
↓ -47.2%
Net Income Profit after all expenses
$-6.09M
↓ -1.0%
Operating Margin Operating profit as % of sales
-126.6%
↑ +27.3% 0th
FCF / Share Free cash flow per share
$-0.24
↑ +87.8%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
95
Cash Quality
66

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters